Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN-3694 + Enzalutamide in mCRPC
NCT02711956Phase 2Completed
- Sponsor
- Zenith Epigenetics
- Start
- Dec 2016
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ZEN3694 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Zenith Epigenetics. Primary endpoints: Incidence of Dose-limiting Toxicities and Incidence of Treatment-emergent Adverse Events and Treatment-related Serious Adverse Events. Started Dec 2016; status: completed.
02
Drugs
ZEN3694
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02711956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711956.